Metotab

Methotrexate, the active ingredient in Metotab, is a folate antagonist presented as an oral tablet for oral use. It is employed in the management of several autoimmune and oncologic conditions, including rheumatoid arthritis, psoriasis, and certain leukemias and lymphomas as well as related blood cancers.

GNH USA supplies Metotab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network adheres to stringent quality standards and regulatory requirements across EU and global markets.

Methotrexate is a folate antagonist used in autoimmune and oncologic disease management. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell replication. - Non‑Hodgkin lymphoma: impedes growth of lymphoma cells. - Ectopic pregnancy: terminates trophoblastic tissue in early implantation.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue and malaise. - Oral mucosal ulceration. - Elevated liver enzymes. - Transient leukopenia or neutropenia. - Diarrhea.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Profound bone marrow suppression leading to pancytopenia. - Acute renal failure. - Life‑threatening cutaneous reactions such as Stevens‑Johnson syndrome. - Opportunistic infections due to immunosuppression.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in pregnant or planning women. - Renal function: assess baseline and monitor; dose adjustment may be needed. - Hepatic health: perform liver function tests before and during therapy. - Hematologic status: regular blood counts to detect myelosuppression. - Concomitant drugs: review for interactions that may increase toxicity. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Methotrexate interacts with several drug classes that can alter its safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other β‑lactam antibiotics: reduce renal clearance, raising plasma levels. - Proton pump inhibitors: may elevate methotrexate concentrations.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: heightened risk of myelosuppression. - Live vaccines: increased chance of infection due to immunosuppression.